Interim report January – March 2023
On April 25, Alligator hosted a webcast for investors, analysts and media, where CEO Søren Bregenholt and CFO Marie Svensson presented and commented on the interim report for January – March 2023.
Click here for a link to the presentation.
Bulletin from the annual general meeting in Alligator Bioscience AB on 26 May 2023
The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedis …
Alligator publishes supplementary prospectus
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, …
Alligator Bioscience Receives FDA Orphan Drug Designation for Mitazalimab in Pancreatic Cancer
Lund, Sweden – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that the U.S. Food and Drug Administration (FDA) has granted O …